Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial
Kausik K. Ray, Ena Oru, Robert S. Rosenson, Jeremiah Jones, Xiaosu Ma, Jennie Walgren, Axel Haupt, Subodh Verma, Daniel Gaudet, Stephen J. Nicholls, Giacomo Ruotolo
Topics & Concepts
Double blindMedicinePlaceboInternal medicinePharmacologyPathologyAlternative medicineLipid metabolism and disordersDiabetes, Cardiovascular Risks, and LipoproteinsLipoproteins and Cardiovascular Health